Company news
Starpharma Holdings Limited news in 2022
Starpharma Holdings Limited's news releases, calls and decks from 2022, newest first.
Starpharma receives $7.1M R&D tax incentive refund
December 22, 2022
VIRALEZE Nasal Spray Registered in Indonesia
December 14, 2022
Positive AZD0466 clinical data presented by AstraZeneca
December 13, 2022
AGM Chairman address and CEO presentation
November 29, 2022
VIRALEZE distribution agreement for Hong Kong and Macau
October 20, 2022
New clinical data for DEP cabazitaxel in prostate cancer
September 11, 2022
S&P DJI Announces September 2022 Quarterly Rebalance
September 2, 2022
Starpharma annual report and full year financial results
August 25, 2022
Starpharma signs new DEP agreement with MSD
August 10, 2022
Quarterly Activities Report & Appendix 4C
July 28, 2022
VIRALEZE Protects Against Omicron in Viral Challenge Model
July 20, 2022
VIRALEZE relaunched by LloydsPharmacy in the UK
June 30, 2022
SPL signs expanded DEP research agreement with US Biopharma
June 26, 2022
SPL7013 in VIRALEZE virucidal against influenza A and B
May 17, 2022
Quarterly Cashflow and Activities Report
April 29, 2022
Quarterly Cashflow and Activities Report
April 28, 2022
VIRALEZE to relaunch in the UK
March 31, 2022
Application for quotation of securities - SPL
March 17, 2022
SPL7013 in VIRALEZE virucidal against Omicron
March 1, 2022
Interim Report and Half-Year Financial Results
February 20, 2022
VIRALEZE sales and distribution in Saudi Arabia and GCC
February 2, 2022
Starpharma - Quarterly Cashflow and Activities Report
January 31, 2022
Starpharma receives $7.7M R&D tax incentive refund
January 19, 2022
Decks in 2022
- Shareholder Meeting (November 2022)
Shareholder meeting · 46 slides · Nov 29, 2022